Drug Utilization Evaluation of Carbapenems in a Teaching Hospital in Tabriz-Iran
Abstract
Background: Carbapenems are beta-lactam antibiotics with broad-spectrum activity for Gram-positive, Gram-negative and anaerobic bacteria and have become the antibiotics of last resort for many serious bacterial infections. The irrational use of carbapenems (imipenem or meropenm) has increased the risk of multi-drug resistant pathogens. The aim of this study was to evaluate the pattern of carbapenem utilization within 9 months and measure compliance with references in Imam Reza Hospital, Tabriz, Iran.
Methods: During 9 months, 100 patients who received carbapenems randomly get selected under the supervision of the attending physician in Imam Reza Hospital affiliated to the Tabriz university of Medical sciences. After coordination with supervisor of each ward, the necessary information was extracted and American Hospital Formulary System (AHFS) and UpToDate 21.3 references were used to assess appropriate indication and accurate dosage of carbapenems.
Results:: The most common cause of prescribing was lower respiratory tract infection (29%). Carbapenems were prescribed for 64% of patients as an appropriate indication. The dose of carbapenems was correct in 74% of patients and duration of carbapenems therapy was correct in 84% of cases. Dose readjustment was necessary for 28 patients, although for 25 of whom it was performed. Only 19 patients had positive culture results.
Conclusion: Despite the global guidelines, carbapenem consumption in health care systems is incorrect. So, comprehensive programs for rational drug use in all medical centers conducted by a clinical pharmacist seems necessary to be employed.
2. Hamishehka H, Ebrahimi D, Mahmoodpoor A, Mashayekh S, Asgharian P, Rezaee H. Drug Utilization Evaluation of Vancomycin in a Teaching Hospital in Tabriz-Iran. Pharm Sci 2015;21(1):25-29
3. Stolar M. Drug use review: operational defenitions. Am J Hosp Pharm 1978;33:225-230.
4. Javadi M, Gholami K, Torkmandi H. Carbapenem Utilization in Critically Ill patients. J Pharm Care 2013;1(4):141-144.
5. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349(9061):1269-76.
6. Al-Niemat SI, Bloukh DT, Al-Harasis MD, Al-Fanek AF, Salah RK. Drug use evaluation of antibiotics prescribed in a Jordanian hospital outpatient and emergency clinics using WHO prescribing indicators. Saudi Med J 2008;29(5):743-8.
7. Sakhaiyan E, Hadjibabaie M, Gholami Kh, et al. Drug utilization evaluation of imipenem in patients undergoing bone marrow transplantation. IJHOSCR 2009;3:10-13.
8. Mousavi S, Behi M, Taghavi M, Ahmadvand A, ZiaieSh, MandanaMoradi. Drug utilization evaluation of imipenem and intravenous ciprofloxacin in a teaching hospital. Iran J Pharm Res 2013;2:161-7.
9. Salehifar E, Shiva A, Moshayedi M, Samiei Kashi T, Chabra A. Drug use evaluation of Meropenem at a tertiary care university hospital: A report from Northern Iran. J Res Pharm Pract 2015;4(4): 222-5.
10. Raveh D, Muallem-Zilcha E, Greenbergn A. Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime,piperacillin-tazobactam and meropenem .Q J Med 2006;99:397-406.
11. Kollef, Marin H. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31:131-8.
12. Meakins MD, Jonathan L, Byron J, Masterson R. Prevention of postoperative infection. ACS Surgery: Principles and Practice 2004: 26-35
Files | ||
Issue | Vol 6, No1-2 (Winter 2018) | |
Section | Original Article(s) | |
Keywords | ||
Drug Utilization Review Carbapenems Hospital |
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |